[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100463441":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":26,"studyPopulation":17,"armGroups":27,"interventions":63,"overallOfficials":17,"centralContacts":81,"locations":87,"responsibleParty":120,"collaborators":17,"id":122,"slug":17,"hasResults":123,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":17,"eligibilityCriteria":127,"healthyVolunteers":123,"sex":128,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":17,"studyType":134,"phases":135,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":90,"whyStopped":17,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Topography","Change in Kmax topography value from baseline","12 Months",[14],{"measure":15,"description":16,"timeFrame":12},"Distance Uncorrected Visual Acuity (UCVA)","Change in Distance UCVA",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":24},"SINGLE",[25],"PARTICIPANT","This is a a dose ranging, multi-center, sham-controlled study to evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking. The study will evaluate safety and efficacy in subjects who have keratoconus.",[28,34,40,45,48,51,54,57],{"label":29,"type":30,"description":31,"interventionNames":32},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 1 \u002F Cohort 1","EXPERIMENTAL","Riboflavin Solution + Exposure to NXL system to achieve total energy level 3",[33],"Combination Product: NXL Energy 3",{"label":35,"type":36,"description":37,"interventionNames":38},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 \u002F Cohort 2A","ACTIVE_COMPARATOR","Riboflavin Solution + Exposure to NXL system to achieve total energy level 1",[39],"Combination Product: NXL Energy 1",{"label":41,"type":36,"description":42,"interventionNames":43},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 \u002F Cohort 2A","Riboflavin Solution + Exposure to NXL system to achieve total energy level 2",[44],"Combination Product: NXL Energy 2",{"label":46,"type":36,"description":31,"interventionNames":47},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 \u002F Cohort 2A",[33],{"label":49,"type":36,"description":37,"interventionNames":50},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 \u002F Cohort 2B",[39],{"label":52,"type":36,"description":42,"interventionNames":53},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 \u002F Cohort 2B",[44],{"label":55,"type":36,"description":31,"interventionNames":56},"Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 \u002F Cohort 2B",[33],{"label":58,"type":59,"description":60,"interventionNames":61},"Placebo Group 2 \u002F Cohort 2B","SHAM_COMPARATOR","Sham Solution with no exposure to NXL System",[62],"Combination Product: Sham Treatment",[64,69,73,77],{"type":65,"name":66,"description":67,"armGroupLabels":68,"otherNames":17},"COMBINATION_PRODUCT","NXL Energy 1","Riboflavin drops + NXL System to Total Energy Level 1",[35,49],{"type":65,"name":70,"description":71,"armGroupLabels":72,"otherNames":17},"NXL Energy 2","Riboflavin drops + NXL System to Total Energy Level 2",[41,52],{"type":65,"name":74,"description":75,"armGroupLabels":76,"otherNames":17},"NXL Energy 3","Riboflavin drops + NXL System to Total Energy Level 3",[29,46,55],{"type":65,"name":78,"description":79,"armGroupLabels":80,"otherNames":17},"Sham Treatment","Sham Drops and No exposure to NXL system",[58],[82],{"name":83,"role":84,"phone":85,"phoneExt":17,"email":86},"Marco Armijo","CONTACT","562-761-7965","marmijo@glaukos.com",[88,102,111],{"facility":89,"status":90,"city":91,"state":92,"zip":93,"country":94,"countryCode":95,"cosmosGeoPoint":96,"geoPoint":101,"contacts":17},"Glaukos Investigative Site","RECRUITING","Dothan","Alabama","36301","United States","US",{"type":97,"coordinates":98},"Point",[99,100],-85.39049,31.22323,{"lat":100,"lon":99},{"facility":89,"status":90,"city":103,"state":104,"zip":105,"country":94,"countryCode":95,"cosmosGeoPoint":106,"geoPoint":110,"contacts":17},"Teaneck","New Jersey","07666",{"type":97,"coordinates":107},[108,109],-74.01597,40.8976,{"lat":109,"lon":108},{"facility":89,"status":90,"city":112,"state":113,"zip":114,"country":94,"countryCode":95,"cosmosGeoPoint":115,"geoPoint":119,"contacts":17},"Westerville","Ohio","43082",{"type":97,"coordinates":116},[117,118],-82.92907,40.12617,{"lat":118,"lon":117},{"type":121,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100463441",false,"NCT05314738","Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus","A Dose Ranging, Multicenter, Sham-Controlled Study to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus","Inclusion Criteria:\n\n* Provide written informed consent\n* Ability to hold gaze sufficiently stable for study testing\n* Willingness and ability to follow all instructions and comply with schedule for follow-up visits\n* Have a diagnosis of keratoconus\n\nExclusion Criteria:\n\n* Known allergy or sensitivity to the test articles or components\n* Any disease causing abnormal topography other than keratoconus\n* Prior or current ocular condition (other than keratoconus) in the study eye that may predispose the eye for future complications","ALL","18 Years","55 Years",{"count":132,"type":133},150,"ESTIMATED","INTERVENTIONAL",[136,137],"PHASE1","PHASE2","Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.",[140],"Progressive Keratoconus",[142,143,144,140],"Eye rubbing","Collagen cross-linking","Keratoconus","2024-07-04",{"date":147,"type":148},"2024-07-08","ACTUAL",{"date":150,"type":148},"2022-03-08",{"date":152,"type":133},"2026-02",{"name":5,"class":6},3]